Jefferies analyst Maury Raycroft downgraded Concert Pharmaceuticals to Hold from Buy after Sun Pharma agreed to acquire all outstanding shares of Concert for an upfront payment of $8.00 per share in cash, or $576M in equity value, plus a non-tradeable contingent value right worth up to an additional $3.50 per share in cash.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNCE:
